Two preclinical sensitization studies were conducted to determine the potential for allergic contact dermatitis with the selegiline transdermal system (STS), a novel transdermal system being developed to treat major depressive disorder. These included a qualitative structure‐activity relationship (QSAR) analysis to assess the allergic dermatitis potential of selegiline, and a guinea pig dermal sensitization study to determine the delayed contact hypersensitivity potential of the STS. In the QSAR analysis, selegiline was classified as a nonallergen. In the guinea pig study, the STS was found not to act as a dermal sensitizer. Thus, based upon the results of these two preclinical studies, treatment with the STS is unlikely to pose a risk of causing significant allergic contact dermatitis. Human data, reported elsewhere, support this hypothesis.
No takes yet. Share an insight, caveat, or question.
Pauporte et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: